Impact, value or economic analyses for diagnostics

E Faulkner, L Annemans, L Garrison, M Helfand, AP Holtorf, J Hornberger, D Hughes, et al. “Challenges in the Development and Reimbursement of Personalized Medicine—Payer and Manufacturer Perspectives and Implications for Health Economics and Outcomes Research: A Report of the ISPOR Personalized Medicine Special Interest Group.” Value Health 15, 1162–1171 (2012).

Rinde, H., C.J. Zech, E. Jonas, K. Bergmann, and A.P. Holtorf. “PMD33 The Impact of Three Different Imaging Strategies on Surgery Planning for Patients With Colorectal Cancer Liver Metastases.” Value in Health 15, no. 7 (November 2012): A350–A351.

Holtorf, A.P., K. Bergmann, M.J. Kim, S. Phongkitkarun, A. Sobhonslidsuk, H. Rinde, and J.M. Lee. “PMD28 Comparing the Cost and Diagnostic Efficiency of Gadoxetic Acid-Enhanced MRI Versus Extracellular Contrast Media-Enhanced MRI and Multidetector Computed Tomography in Patients With Suspected Hepatocellular Carcinoma in Thailand and Korea.” Value in Health 15, no. 7 (November 2012): A349–A350.

Holtorf, A.P., K. Bergmann, M.J. Kim, S. Phongkitkarun, A. Sobhonslidsuk, H. Rinde, and J.M. Lee. “Comparing the Cost and Diagnostic Efficiency of Gadoxetic Acid-Enhanced MRI  Tomography in Patients With Suspected Hepatocellular Carcinoma in Thailand and Korea.” Value in Health 15, no. 7 (November 2012): A349–A350; PMD28. doi:10.1016/j.jval.2012.08.877.

Harald Rinde, MD, MBA, Anne Rubin, MBA. Cost-effectiveness of the cardiovascular marker ST2 in providing risk stratification after acute heart failure.[ISPOR 14th Annual European Congress, Madrid] Nov 2011.

Sean D. Sullivan, PhD, Louis P. Garrison, PhD, Harald Rinde, PhD, Janice Kolberg, PhD, Edward Mohler PhD. “Cost-Effectiveness of Risk Stratification for Preventing Type 2 Diabetes Using A Multi-Marker Diabetes Risk Score”. [Journal of Medical Economics Vol. 14, No. 5, 2011, 609–616] Jul 2011.

Stephen Williams, Rachel Ostroff, Mark Messenbaugh, Harald Rinde, Lou Riceberg, York Miller, Harvey Pass. How Good is Good Enough? An Evaluation of Minimum Performance Standards for Acceptance of New Diagnostic Tests in Lung Cancer. [American Thoracic Society International Conference, Denver] May 2011.

Faulkner, Eric C, AP Holtorf, M Longacre, and Lieven Annemans. 2011. Value-Based Reimbursement For Personalized Medicine: Where Do We Stand? ‘Value in Health‘. Madrid, Spain, November.

Edward J. Moler, PhD , Louis P. Garrison, Jr, PhD,  Harald Rinde, MD, MBA, Janice Kolberg, PhD , Sean D. Sullivan, PhD. “The Value of Personalized, Predictive Risk-assessment Tools for the Prevention of Chronic Diseases”. JSM 2010 (Joint Statistical Meeting, Ontario, Jul-2010.

Sean D. Sullivan, Richard Polluck, Louis P. Garrison, Harald Rinde, Janice Kolberg. “Long-Term Cost-Effectiveness of a Diabetes Risk Score”. [American Diabetes Associations 69th Scientific Sessions in New Orleans.  Scientific Sessions Abstract Book, the June 2009 supplement to the journal Diabetes] Jun-2009

Sean D. Sullivan, Louis P. Garrison, Harald Rinde, Janice Kolberg, Edward Moler and Mickey Urdea. “Long-Term Cost Effectiveness of a Diabetes Risk Score in Clinical Practice”. [ISPOR Thirteenth Annual International, New Orleans.  Value in Health, International Society for Pharmacoeconomics and Outcomes Research, Volume 11 Issue 3, Pages A322 -353 May/June 2008].

A.-P. Holtorf (2006)  BioValley Seminar Series “Creating Value with Diagnostics”